Top Page
Archer Materials
(Sydney:AXE)
Archer Materials (AXE) vs. iShares MSCI Australia ETF (EWA)
Archer Materials Business Overview & Revenue Model
Archer Materials Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.06M | 2.06M | 2.14M | 1.50M | 973.00K | 467.66K |
| Gross Profit | 2.06M | 2.06M | 2.14M | -53.74K | 922.59K | 435.36K |
| EBITDA | -6.94M | -6.94M | -5.11M | -8.66M | -14.97M | -3.24M |
| Net Income | -6.97M | -6.97M | -4.80M | -9.05M | -14.12M | -7.84M |
Balance Sheet | ||||||
| Total Assets | 17.47M | 17.47M | 22.89M | 27.21M | 30.17M | 19.69M |
| Cash, Cash Equivalents and Short-Term Investments | 13.82M | 13.82M | 18.78M | 24.19M | 28.17M | 8.93M |
| Total Debt | 14.97K | 14.97K | 109.31K | 9.10K | 19.75K | 30.09K |
| Total Liabilities | 752.16K | 752.16K | 1.09M | 1.21M | 746.23K | 732.71K |
| Stockholders Equity | 16.72M | 16.72M | 21.80M | 26.00M | 29.42M | 18.96M |
Cash Flow | ||||||
| Free Cash Flow | -4.19M | -4.19M | -4.99M | -3.21M | -4.44M | -2.32M |
| Operating Cash Flow | -4.19M | -4.19M | -4.79M | -3.03M | -4.30M | -2.22M |
| Investing Cash Flow | 4.11M | 4.11M | 6.98M | 2.31M | -94.83K | -262.25K |
| Financing Cash Flow | -96.30K | -96.30K | -115.82K | 64.90K | 24.62M | 606.22K |
Archer Materials Technical Analysis
Archer Materials Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | AU$61.40M | 4.50 | 13.76% | 5.97% | -18.05% | -51.45% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
59 Neutral | AU$1.20B | -29.00 | -50.48% | ― | 333.23% | 10.83% | |
49 Neutral | AU$99.39M | -13.69 | -35.59% | ― | ― | -45.74% | |
48 Neutral | AU$92.03M | -31.25 | ― | ― | 44.80% | 7.69% | |
43 Neutral | AU$22.67M | -2.12 | -112.59% | ― | ― | -67.74% | |
38 Underperform | AU$368.12M | -9.12 | -149.70% | ― | 503.29% | 11.46% |
Archer Materials Corporate Events
Archer Materials has released the presentation that its CEO Simon Ruffell will deliver during an investor webinar scheduled for 11:00am AEDT on 29 January 2026, which will be followed by a Q&A session. The event underlines the company’s ongoing investor engagement and provides a platform to update shareholders on its Q2 FY26 progress and strategic developments in quantum and semiconductor technologies.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.45 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
In the December quarter of FY26, Archer Materials reported significant technical and strategic progress across its core quantum and biochip programs, including improved quantum state readout for its carbon-based qubit materials, successful synthesis of this material on a one‑inch silicon wafer, and demonstration of room-temperature spin lifetimes that compare favourably with leading quantum platforms. The company broadened its ecosystem by signing a collaboration with Emergence Quantum to explore graphene and carbon-based technologies for next-generation quantum and electronic devices, entered an agreement with CSIRO to develop quantum machine learning models for enhanced financial fraud detection, and, in its Biochip program, achieved clinical-standard accuracy for silicon-based blood potassium testing devices in collaboration with IMEC, a shift that could lower costs, de-risk supply chains and accelerate regulatory and commercial pathways; Archer ended the quarter with $10.3 million in cash (excluding a subsequent $2.1 million R&D tax rebate) and strengthened its board with the appointment of experienced health industry executive Andrew Just as a non-executive director.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.45 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
Archer Materials has announced it will host an investor webinar to deliver its quarterly update for the period ended 31 December 2025, with CEO Simon Ruffell presenting and taking questions from participants. The event underscores the company’s ongoing engagement with investors as it advances its portfolio of quantum and semiconductor technologies, providing stakeholders with an opportunity to gain insights into recent developments and the company’s strategic progress.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.45 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
Archer Materials has reported significant technical progress across its quantum computing, quantum sensing and Biochip programs in 2025 and laid out a commercial roadmap for 2026. The company advanced its carbon-based quantum technology by demonstrating electrical gating in single electron transistor devices, improving electron spin lifetimes to 800 nanoseconds, and achieving qubit control through new resonator circuits, collectively de-risking the path toward a functional qubit demonstration targeted for early 2026 and positioning the platform for scalable manufacturing. Archer also expanded its quantum sensing and quantum machine learning initiatives, including a fraud-detection project for financial transactions that could be adapted to broader applications. In parallel, its Biochip program for blood potassium monitoring reached precision levels aligned with clinical lab standards and progressed toward manufacturable silicon- and graphene-based prototypes with partners such as IMEC, supporting future external trials and potential expansion into additional biomarkers. Management frames 2026 as an inflection year in which all core programs are expected to move from research-led development toward product demonstrations and commercial partnerships, signalling a shift toward real-world deployments and active commercial engagement.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
Archer Materials Limited announced that Kenneth Graham Williams has ceased to be a director as of December 1, 2025. Williams held 3,000,000 unlisted options through the KG & PC Williams Family Trust, which are exercisable at $0.5344 each and expire on June 30, 2028. This change in directorship may impact the company’s governance and strategic direction.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
Archer Materials Limited has announced the appointment of Andrew Ian Just as a new director, effective from December 1, 2025. This appointment is part of the company’s strategic efforts to strengthen its leadership team, although the new director currently holds no securities or interests in the company. This move is expected to enhance Archer Materials’ governance and potentially influence its strategic direction and stakeholder relations.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
Archer Materials Limited has announced changes to its board with the appointment of Andrew Just as a Non-Executive Director and the retirement of Ken Williams. Andrew Just brings extensive experience in the medical device and healthcare industries, which aligns with Archer’s strategic growth in medical diagnostics technologies. The board expressed gratitude to Ken Williams for his significant contributions over the past five years, including overseeing the company’s transition from mineral exploration to a quantum and medical device company.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.39 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
Archer Materials Limited has announced a change in the director’s interest, specifically involving Gregory David English. The change includes the issuance of 660,867 Performance Rights following shareholder approval at the company’s Annual General Meeting. This adjustment in director’s interest reflects the company’s ongoing governance practices and may influence stakeholder perceptions regarding leadership alignment with company goals.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
Archer Materials Limited has announced the presentation to be delivered by its CEO, Dr. Simon Ruffell, at the company’s Annual General Meeting. This announcement underscores Archer’s ongoing commitment to innovation in the semiconductor sector, particularly in quantum computing and medical diagnostics, which could significantly impact its market positioning and stakeholder interests.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
Archer Materials has partnered with CSIRO, Australia’s National Science Agency, to develop Quantum Machine Learning (QML) models aimed at enhancing fraud detection in financial transactions. This collaboration, running from November 2025 to November 2026, seeks to leverage CSIRO’s expertise to create innovative QML models that offer improved reliability and speed in identifying fraudulent activities. The project underscores Archer’s strategy to commercialize near-term quantum applications with global impact, potentially extending QML’s applications beyond finance to sectors like healthcare, energy, and cybersecurity.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.
Archer Materials Limited announced the cessation of 123,879 performance rights due to unmet conditions, impacting its issued capital structure. This development may influence the company’s strategic planning and stakeholder perceptions, as performance rights are often linked to employee incentives and company growth targets.
The most recent analyst rating on (AU:AXE) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Archer Materials stock, see the AU:AXE Stock Forecast page.